Blockade of complement activation product C5a activity using specific antibody attenuates intestinal damage in trinitrobenzene sulfonic acid induced model of colitis

Laboratory Investigation

Volumn 91, Issue 3, 2011, Pages 472-483

  Chen, Guojiang ^a   Yang, Yuemei ^a,b   Gao, Xudong ^b   Dou, Yan ^c   Wang, Huihui ^a,d   Han, Gencheng ^a   Wang, Renxi ^a   Wang, Jianan ^a   Wang, Liyan ^a   Li, Xinying ^a   Guo, Renfeng ^e   Xiao, He ^a   Shen, Beifen ^a   Li, Yan ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b TIANJIN UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d INNER MONGOLIA MEDICAL COLLEGE   (China)

^e InflaRx GmbH   (Germany)

Author keywords

antibody based therapy; complement C5a; neutrophil; Th2 response; TNBS colitis

Indexed keywords

CHEMOKINE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; CYTOKINE; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY; PREDNISOLONE; TRINITROBENZENESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; COLITIS; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; GENE EXPRESSION REGULATION; HEMOLYSIS; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; INNATE IMMUNITY; INTESTINE INJURY; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; TH2 CELL; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, NEUTRALIZING; COLITIS; COLON; COMPLEMENT ACTIVATION; COMPLEMENT C5A; CYTOKINES; HUMANS; IMMUNOTHERAPY; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; LYMPHOCYTE COUNT; MALE; MICE; MICE, INBRED BALB C; NEUTROPHIL INFILTRATION; RECEPTOR, ANAPHYLATOXIN C5A; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; TH2 CELLS; TIME FACTORS; TRINITROBENZENESULFONIC ACID;

EID: 79952081601     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2010.183     Document Type: Article

References (53)

1. Fiorucci C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182-205.
2. Elson CO, Sartor RB, Tennyson GS, et al. Experimental models of inflammatory bowel disease. Gastroenterology 1995;109:1344-1367.
3. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002;20:495-549. (Pubitemid 34293433)
4. McGovern D, Powrie F. The IL-23 axis plays a key role in the pathogenesis of IBD. Gut 2007;56:1333-1336. (Pubitemid 47517817)
5. Hue S, Ahern P, Buonocore S, et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med 2006;203:2473-2483. (Pubitemid 44664617)
6. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-434. (Pubitemid 47123518)
7. Fiorucci S, Mencarelli A, Palazzetti B, et al. Importance of innate immunity and collagen binding integrin a1b1 in TNBS-induced colitis. Immunity 2002;17:769-780. (Pubitemid 35477796)
8. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000;68:7010-7017. (Pubitemid 32463415)
9. Nenci A, Becker C, Wullaert A, et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 2007;446:557-561. (Pubitemid 46514732)
10. Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol 2005;23:821-852. (Pubitemid 40563186)
11. Robbins RA, Russ WD, Rasmussen JK, et al. Activation of the complement system in the adult respiratory distress syndrome. Am Rev Respir Dis 1987;135:651-658. (Pubitemid 17041600)
12. Linton SM, Morgan BP. Complement activation and inhibition in experimental models of arthritis. Mol Immunol 1999;36:905-914. (Pubitemid 30100843)
13. Welch TR. Complement in glomerulonephritis. Nat Genet 2002;31: 333-334. (Pubitemid 35154438)
14. Ffrench-Constant C. Pathogenesis of multiple sclerosis. Lancet 1994; 343:271-275. (Pubitemid 24039632)
15. Arumugam TV, Shiel IA, Woodruff TM, et al. The role of the complement system in ischemia-reperfusion injury. Shock 2004;21:401-409.
16. Hawlisch H, Wills-karp M, Karp CL, et al. The anaphylatoxins bridge innate and adaptive immune responses in allergic asthma. Mol Immunol 2004;41:123-131. (Pubitemid 38668621)
17. Marder SR, Chenoweth DE, Goldstein IM, et al. Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg. J Immunol 1985;134:3325-3331. (Pubitemid 15246474)
18. Riedemann NC, Guo RF, Sarma VJ, et al. Expression and function of the C5a receptor in rat alveolar epithelial cells. J Immunol 2002;168: 1919-1925. (Pubitemid 34135794)
19. Laudes IJ, Chu JC, Huber-Lang M, et al. Expression and function of C5a receptor in mouse microvascular endothelial cells. J Immunol 2002;169:5962-5970. (Pubitemid 35299387)
20. Werfel T, Oppermann M, Schulze M, et al. Binding of fluoresceinlabeled anaphylatoxin C5a to human peripheral blood, spleen, and bone marrow leukocytes. Blood 1992;79:152-160.
21. Haviland DL, McCoy RL, Whitehead WT, et al. Cellular expression of the C5a anaphylatoxin receptor (C5aR): demonstration of C5Ar on nonmyeloid cells of the liver and lung. J Immunol 1995;154:1861-1869.
22. Schieferdecker HL, Schlaf G, Jungermann K, et al. Functions of anaphylatoxin C5a in rat liver: direct and indirect actions on nonparenchymal and parenchymal cells. Int Immunopharmacol 2001;1:469-481. (Pubitemid 32197545)
23. Kolios G, Petoumenos C, Nakos A. Mediators of inflammation: production and implication in inflammatory bowel disease. Hepatogastroenterology 1998;45:1601-1609. (Pubitemid 28515168)
24. Laufer J, Katz Y, Passwell JH. Extrahepatic synthesis of complement proteins in inflammation. Mol Immunol 2001;38:221-229. (Pubitemid 32786779)
25. Nieuwenhuis EE, Neurath MF, Corazza N, et al. Disruption of T helper 2- immune responses in Epstein-Barr virus-induced gene 3-deficient mice. Proc Natl Acad Sci USA 2002;99:16951-16956. (Pubitemid 36034079)
26. Neurath MF, Weigmann B, Finotto S, et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med 2002;195:1129-1143. (Pubitemid 34517139)
27. Xu R, Wang R, Han G, et al. Complement C5a regulates interleukine-17 by affecting the crosstalk between DCs and gd T cells in CLP-induced sepsis. Eur J Immunol 2010;40:1079-1088.
28. Van der Heijden PJ, Stok W. Improved procedure for the isolation of functionally active lymphoid cells from the murine intestine. J Immunol Methods 1987;103:161-167. (Pubitemid 17153863)
29. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 1984;87: 1344-1350. (Pubitemid 15201434)
30. Bock D, Martin U, Gärtner S, et al. The C terminus of the human C5a receptor (CD88) is required for normal ligand-dependent receptor internalization. Eur J Immunol 1997;27:1522-1529. (Pubitemid 27254846)
31. Pushparaj PN, Tay HK, Wang CC, et al. VAMP8 is essential in anaphylatoxin-induced degranulation, TNF-a secretion, peritonitis, and systemic inflammation. J Immunol 2009;183:1413-1418.
32. Issuree PD, Pushparaj PN, Pervaiz S, et al. Resveratrol attenuates C5a-induced inflammatory responses in vitro and in vivo by inhibiting phospholipase D and sphingosine kinase activities. FASEB J 2009;23: 2412-2424.
33. Guo RF, Riedemann NC, Bernacki KD, et al. Neutrophil C5a receptor and the outcome in a rat model of sepsis. FASEB J 2003;13: 1889-1891.
34. Morgan BP. Mechanisms of tissue damage by the membrane attack complex of complement. Complement Inflamm 1989;6:104-111. (Pubitemid 19096123)
35. Struyf S, Gouwy M, Dillen C, et al. Chemokines synergize in the recruitment of circulating neutrophils into inflamed tissue. Eur J Immunol 2005;35:1583-1591. (Pubitemid 40703864)
36. Distelmaier K, Adlbrecht C, Jakowitsch J, et al. Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction. Thromb Haemost 2009;102: 564-572.
37. Alex P, Zachos NC, Nguyen T, et al. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis 2009;15:341-352.
38. Daniel C, Sartory NA, Zahn N, et al. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther 2008;324:23-33. (Pubitemid 350294165)
39. Ahrenstedt O, Knutson L, Nilsson B, et al. Enhanced local production of complement components in the small intestines of patients with Crohn's disease. N Eng J Med 1990;322:1345-1349. (Pubitemid 20154477)
40. Berstad AE, Brandzaeg P. Expression of cell membrane complement regulatory glycoproteins along the normal and diseased human gastrointestinal tract. Gut 1998;42:522-529. (Pubitemid 28186570)
41. Berstad AE, Brandzaeg P, Stave R, et al. Epithelium related deposition of activated complement in Helicobacter pylori-associated gastritis. Gut 1997;40:196-203. (Pubitemid 27093093)
42. Andoh A, Kinoshita K, Rosenberg I, et al. Intestinal trefoil factor induces decay-accelerating factor expression and enhances the protective activities against complement activation in intestinal epithelial cells. J Immunol 2001;167:3887-3893. (Pubitemid 32910833)
43. Johswich K, Martin M, Bleich A, et al. Role of the C5a receptor (C5aR) in acute and chronic dextran sulfate-induced models of inflammatory bowel disease. Inflamm Bowel Dis 2009;15:1812-1823.
44. Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol 2007;25:1265-1275. (Pubitemid 350089828)
45. Woodruff TM, Arumugam TV, Shiels IA, et al. A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J Immunol 2003;171:5514-5520. (Pubitemid 37432841)
46. Walport MJ. Complement. First of two parts. N Engl J Med 2001;344: 1058-1066.
47. Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumor necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991;32:913-917.
48. Murch SH, Braegger CP, Walker-Smith JA, et al. Location of tumor necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993;34:1705-1709. (Pubitemid 23353163)
49. Kojouharoff G, Hans W, Obermeier F, et al. Neutralization of tumor necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol 1997;107:353-358. (Pubitemid 27049264)
50. Schenk M, Bouchon A, Seibold F, et al. TREM-1-expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases. J Clin Invest 2007;117:3097-3106. (Pubitemid 47529639)
51. Kamada N, Hisamatsu T, Okamoto S, et al. Unique CD14+ intestinal macrophages contribute to the pathogenesis of Crohn's disease via IL- 23/IFN-g axis. J Clin Invest 2008;118:2269-2280. (Pubitemid 351872344)
52. Smith PD, Ochsenbauer-Jambor C, Smythies LE. Intestinal macrophages: unique effector cells of the innate immune system. Immunol Rev 2005; 206:149-159. (Pubitemid 41105168)
53. Strainic MG, Liu J, Huang D, et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to na?̈ve CD4+ T cells. Immunity 2008;28:425-435.